Myriad(MYGN) ZACKS·2025-02-25 00:00Group 1 - Myriad Genetics reported quarterly earnings of 0.04 per share a year ago [1] - The company posted revenues of 196.6 million year-over-year [2] - Myriad has surpassed consensus revenue estimates four times over the last four quarters [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call [3] - Myriad shares have increased approximately 3.4% since the beginning of the year, outperforming the S&P 500's gain of 2.2% [3] Group 3 - The earnings outlook for Myriad is uncertain, with current consensus EPS estimates at breakeven on 0.09 on $859.09 million in revenues for the current fiscal year [7] - The estimate revisions trend for Myriad is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 4 - The Medical - Biomedical and Genetics industry is currently in the top 26% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5]